In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RTX Healthcare gets US nod for Telehealth monitor:

This article was originally published in Clinica

Executive Summary

RTX Healthcare has received 510(k) clearance from the US FDA for its RTX3370 Telehealth monitor for patients outside hospitals. The system, designed to allow patients with chronic diseases to live more independently, monitors patients' vital signs from peripheral devices and collates subjective patient information from questionnaires; it then transmits the data to a central clinical information system. Peripheral devices that can be used with the Telehealth Monitor include scales, blood pressure monitors, blood glucose meters, peak flow meters and oxygen saturation meters. Noerresundby, Denmark-based RTX recently joined the Continua Health Alliance - a non-profit group working towards deciding the best technical standards for home healthcare monitoring. RTX Healthcare is a division of Nordic-listed company RTX Telecom.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel